Dr Kasia Siemienowicz is a Lecturer of Biomedical Science in the School of Applied Sciences at Edinburgh Napier University, Scotland, UK.
Kasia’s research focuses upon understanding how altered hormonal exposure during fetal life affects development and predisposition to adult disease, to ensure best lifelong health opportunities for our children and providing information regarding possible treatment routes.
Kasia has a BSc (Hons) in Biomedical Sciences from the Edinburgh Napier University and MSc by Research (with Distinction) in Reproductive Sciences from the University of Edinburgh. In 2013 she was awarded an MRC Studentship to study for her PhD in the lab of Prof. Colin Duncan at QMRI Centre for Reproductive Health, the University of Edinburgh. She was awarded her PhD in 2017 with a thesis examining causes and consequences of dysregulation in an ovine model of PCOS. Following on from her PhD she has worked as a Research Fellow in the laboratory of Prof. Mick Rae at Edinburgh Napier University and in the laboratory of Prof. Colin Duncan at the University of Edinburgh.
Kasia is a member of Society for Reproduction and Fertility, Royal Society of Biology, Endocrine Society, and Associate Fellow of the Higher Education Academy.
In the past years Kasia won two prestigious awards: Young Investigator Award from the European Society of Endocrinology (for her work on the role of the adipose tissue in the pathology of the Polycystic Ovary Syndrome (PCOS), and best postgraduate student prize from the Society of Reproduction and Fertility (for her research on mechanistic underpinnings of obesity in PCOS). She was also shortlisted as a finalist for the Scottish Universities Life Sciences Alliance (SULSA) Early Career Researcher Prize, which awards outstanding early career scientists whose work shows excellent potential to make impact in the field of life sciences. Kasia’s research on the nature of obesity in PCOS and its therapeutic amelioration was featured in the New Scientist magazine. Her research has also illuminated a number of potential novel therapeutic routes, and these are now the underpinnings of both publications and funding applications.